Results 11 to 20 of about 779,655 (355)

Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome [PDF]

open access: yes, 2016
There is evidence from animal and in-vitro studies that activation of the endocannabinoid system (EC) through cannabinoid receptor 1 (CB-1) is associated with liver injury, inflammation and hepatocellular carcinoma.1 Data suggests endogenous cannabinoids
Ahmed, Lina   +6 more
core   +1 more source

Effect of Wakame and Carob Pod Snacks on Non-Alcoholic Fatty Liver Disease [PDF]

open access: yes, 2019
Snacks combining different functional ingredients could represent a useful therapeutic strategy against NAFLD. The present study aimed to analyze the effect of two snack formulations based on carob and wakame flour in the treatment for NAFLD in rats. For
Aguirre López, Leixuri   +6 more
core   +2 more sources

Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis

open access: yesLipids in Health and Disease, 2019
Background Ceramide plays pathogenic roles in nonalcoholic fatty liver disease (NAFLD) via multiple mechanisms, and as such inhibition of ceramide de novo synthesis in the liver may be of therapeutically beneficial in patients with NAFLD.
Rui-Xu Yang   +11 more
doaj   +1 more source

In-depth analysis of de novo lipogenesis in non-alcoholic fatty liver disease: Mechanism and pharmacological interventions

open access: yesLiver Research, 2023
Non-alcoholic fatty liver disease (NAFLD) is characterized by the abnormal buildup of lipids in the liver tissue. Non-alcoholic fatty liver (NAFL) may progress to non-alcoholic steatohepatitis.
Zhixian Zhu   +4 more
doaj   +1 more source

Association Between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Risk of Non-alcoholic Fatty Liver Disease: A Cross-Sectional Study

open access: yesFrontiers in Medicine, 2022
Background:Non-alcoholic fatty liver disease (NAFLD) is a global health problem affecting more than a quarter of the entire adult population. Both monocytes and high-density lipoprotein cholesterol (HDL-C) were found to participate in the progression of ...
Liping Wang   +8 more
doaj   +1 more source

Vitamin D3 supplementation of a high fat high sugar diet ameliorates prediabetic phenotype in female LDLR–/–and LDLR+/+mice [PDF]

open access: yes, 2017
© 2017 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. INTRODUCTION: Fatty liver disease is prevalent in populations with high caloric intake.
Asai   +50 more
core   +1 more source

Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota

open access: yesScientific Reports, 2017
Non-alcoholic steatohepatitis (NASH) is an epidemic metabolic disease with limited therapeutic strategies. Cumulative data support the pivotal role of gut microbiota in NASH.
Da Zhou   +6 more
doaj   +1 more source

Oxidative stress: new insights on the association of nonalcoholic fatty liver disease and atherosclerosis [PDF]

open access: yes, 2015
Non-alcoholic fatty liver disease (NAFLD) represents the most common and emerging chronic liver disease worldwide. It includes a wide spectrum of liver diseases ranging from simple fatty liver to non-alcoholic steatohepatitis (NASH), which may progress ...
Albanese, Fabiana   +7 more
core   +1 more source

Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression

open access: yesExperimental and Molecular Medicine, 2018
Fatty liver disease: A gutsy way to prevent disease progression A treatment for non-alcoholic fatty liver disease that incorporates a metabolite found in the gut could prevent progression to a more serious liver condition. Drugs that enhance the activity
Da Zhou   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy